KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Common Equity (2016 - 2025)

Historic Common Equity for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $7.3 billion.

  • Quest Diagnostics' Common Equity rose 663.65% to $7.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year increase of 663.65%. This contributed to the annual value of $6.8 billion for FY2024, which is 742.67% up from last year.
  • As of Q3 2025, Quest Diagnostics' Common Equity stood at $7.3 billion, which was up 663.65% from $7.3 billion recorded in Q2 2025.
  • Quest Diagnostics' 5-year Common Equity high stood at $7.3 billion for Q3 2025, and its period low was $5.9 billion during Q4 2022.
  • Its 5-year average for Common Equity is $6.5 billion, with a median of $6.5 billion in 2023.
  • In the last 5 years, Quest Diagnostics' Common Equity surged by 1906.01% in 2021 and then plummeted by 853.0% in 2022.
  • Quarter analysis of 5 years shows Quest Diagnostics' Common Equity stood at $6.5 billion in 2021, then dropped by 8.53% to $5.9 billion in 2022, then increased by 6.95% to $6.3 billion in 2023, then rose by 7.43% to $6.8 billion in 2024, then rose by 7.07% to $7.3 billion in 2025.
  • Its last three reported values are $7.3 billion in Q3 2025, $7.3 billion for Q2 2025, and $7.0 billion during Q1 2025.